Peptide carrier-mediated non-covalent delivery of unmodified cisplatin, methotrexate and other agents via intravenous route to the brain

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Sarkar, Gobinda ^a   Curran, Geoffry L ^a   Sarkaria, Jann N ^a   Lowe, Val J ^a   Jenkins, Robert B ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CETUXIMAB; CISPLATIN; DRUG CARRIER; DYE; EVANS BLUE; INSULIN; LIGAND; METHOTREXATE; PEPTIDE; PEPTIDE DERIVATIVE; PROTEIN K16APOE; RADIOISOTOPE; UNCLASSIFIED DRUG; COLORING AGENT; RADIOACTIVE IODINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN LEVEL; CONTROLLED STUDY; COVALENT BOND; DRUG DELIVERY SYSTEM; DRUG MIXTURE; FEMALE; FEMORAL VEIN; LIGAND BINDING; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; PASSIVE TRANSPORT; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MOLECULAR GENETICS; TRANSPORT AT THE CELLULAR LEVEL;

AMINO ACID SEQUENCE; ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CISPLATIN; COLORING AGENTS; DRUG CARRIERS; FEMALE; INJECTIONS, INTRAVENOUS; INSULIN; IODINE RADIOISOTOPES; METHOTREXATE; MICE; MOLECULAR SEQUENCE DATA; PEPTIDES;

EID: 84901342070     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097655     Document Type: Article

References (49)

1. Banks WA (1999) Physiology and pathology of the blood-brain barrier: implications for microbial pathogenesis, drug delivery and neurodegenerative disorders. J Neurovirol 5: 538-555.
2. Lee J-H, Hua Lu H (2011) Chimeric p53 as an alternative therapy for hypoxic tumors. Cancer Biol Ther. 11: 108-110.
3. Hdeib A, Sloan AE (2011) Convection-enhanced delivery of 131I-chTNT-1/B mAB for treatment of high-grade adult gliomas. Expert Opin Biol Ther. 11: 799-806.
4. Kioi M, Husain SR, Croteau D, Kunwar S, Puri RK (2006) Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy. Technol Cancer Res Treat.; 5: 239-50. (Pubitemid 43946257)
5. Choi JJ, Feshitan JA, Baseri B, Wang S, Tung YS, et al. (2010) Microbubble-size dependence of focused ultrasound-induced blood-brain barrier opening in mice in vivo. IEEE Trans Biomed Eng. 57: 145-54.
6. Groothuis DR (2000) The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol. 2: 45-59.
7. Siegal T, Zylber-Katz E (2002) Strategies for increasing drug delivery to the brain: focus on brain lymphoma. Clin Pharmacokinet. 41: 171-86. (Pubitemid 34415836)
8. Bellavance MA, Blanchette M, Fortin D (2008) Recent advances in blood-brain barrier disruption as a CNS delivery strategy. AAPS J.; 10: 166-77.
9. Steeg PS, Camphausen KA (2011) Smith QR. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer. 11: 352-63.
10. Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, et al. (1984) Transferrin receptor on endothelium of brain capillaries. Nature; 312: 162-163. (Pubitemid 14000081)
11. Zlokovic BV, Jovanovic S, Miao W, Samara S, Verma S, et al. (2000) Differential regulation of leptin transport by the choroid plexus and blood-brain barrier and high affinity transport systems for entry into hypothalamus and across the blood-cerebrospinal fluid barrier. Endocrinology. 141: 1434-1441. (Pubitemid 32269111)
12. Spencer BJ, Verma IM (2007) Targeted delivery of proteins across the blood-brain barrier. Proc Natl Acad Sci U S A. 104: 7594-7599. (Pubitemid 47185951)
13. Wang D, El-Amouri SS, Dai M, Kuan C-Y, Hui DY, et al. (2013) Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrier. PNAS 110: 2999-3004.
14. Boado RJ, Hui EK, Lu JZ, Pardridge WM (2010) Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. J Pharmacol Exp Ther. 333: 961-969.
15. Deeken JF, Löscher W (2007) The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res. 13: 1663-1674. (Pubitemid 46952931)
16. Dietz GP, Bähr M (2004) Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci. 27: 85-131. (Pubitemid 39370094)
17. Karkan D, Pfeifer C, Vitalis TZ, Arthur G, Ujiie M, et al. (2008) A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier. PLoS One. 3: e2469.
18. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285: 1569-1572. (Pubitemid 29420581)
19. Zhou J, Patel TR, Sirianni RW, Strohbehn G, Zheng MQ, et al. (2013) Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma. Proc Natl Acad Sci U S A. 110: 11751-6.
20. Allard E, Passirani C, Benoit JP (2009) Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials 30: 2302-18.
21. Sarkar G, Curran GL, Mahlum E, Decklever T, Wengenack TM, et al. (2011) A carrier for non-covalent delivery of functional beta-galactosidase and antibodies against amyloid plaques and IgM to the brain. PLoS One. 6(12): e28881.
22. Carlson SK, Classic KL, Hadac EM, Bender CE, Kemp BJ, et al. (2006) In vivo quantitation of intratumoral radioisotope uptake using micro-single photon emission computed tomography/computed tomography. Mol Imaging Biol. 8: 324-32. (Pubitemid 44741369)
23. Mouzon A, Kerger J, D'Hondt L, Spinewine A (2013) Potential Interactions with Anticancer Agents: A Cross-Sectional Study. Chemotherapy. 59: 85-92.
24. Kudawara I, Aoki Y, Ueda T, Araki N, Naka N, et al. (2013) Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan. J Chemother.; 25: 41-8.
25. Lillehei KO, Kong Q, Withrow SJ, Kleinschmdt-DeMasters B (1996) Efficacy of intralesionally administered cisplatin-impregnated biodegradable polymer for the treatnment of 9L gliosarcoma in the rat. Neurosurgery. 39: 1191-7.
26. Dhanikula RS, Argaw A, Bouchard JF, Hildgren P (2008) Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability. Mol Pharm. 5: 105-16. (Pubitemid 351300040)
27. Minami T, Okazaki J, Kawabata A, Kuroda R, Okazaki Y (1998) Penetration of cisplatin into mouse brain by lipopolysaccharide. Toxicology. 130: 107-13. (Pubitemid 28488579)
28. Angelov L, Doolittle ND, Kraemer DF, Siegal T, Barnett GH, et al. (2009) Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J Clin Oncol. 27: 3503-9.
29. Banks WA, Owen JB, Erickson MA (2012) Insulin in the brain: there and back again. Pharmacol Ther. 136: 82-93.
30. Marquet F, Tung YS, Teichert T, Ferrera VP, Konofagou EE (2011) Noninvasive, transient and selective blood-brain barrier opening in non-human primates in vivo. PLoS One; 6: e22598.
31. Blanchette M, Fortin D (2011) Blood-brain barrier disruption in the treatment of brain tumors. Methods Mol Biol. 686: 447-63.
32. Cosolo WC, Martinello P, Louis WJ, Christophidis N (1989) Blood-brain barrier disruption using mannitol: time course and electron microscopy studies. Am J Physiol. 256: R443-7.
33. Deng CX (2010) Targeted drug delivery across the blood-brain barrier using ultrasound technique.Ther Deliv. 1: 819-848
34. Mesiwala AH, Farrell L, Wenzel HJ, Silbergeld DL, Crum LA, et al. (2002) High-intensity focused ultrasound selectively disrupts the blood-brain barrier in vivo. Ultrasound Med Biol. 28: 389-400. (Pubitemid 34308920)
35. Sheikov N, McDannold N, Vykhodtseva N, Jolesz F, Hynynen K (2004) Cellular mechanisms of the blood-brain barrier opening induced by ultrasound in presence of microbubbles. Ultrasound Med Biol. 30: 979-89. (Pubitemid 39094314)
36. Hynynen K, McDannold N, Vykhodtseva N, Raymond S, Weissleder R, et al. (2006) Focal disruption of the blood-brain barrier due to 260-kHz ultrasound bursts: a method for molecular imaging and targeted drug delivery. J Neurosurg. 105: 445-54. (Pubitemid 44358757)
37. Waterhouse RN (2003) Determination of lipophilicity and its use as a predictor of bloodbrainbarrier penetration of molecular imaging agents. Mol Imaging Biol. 5: 376-89.
38. Greig NH, Daly EM, Sweeney DJ, Rapoport SI (1990) Pharmacokinetics of chlorambuciltertiarybutyl ester, a lipophilic chlorambucil derivative that achieves and maintains highconcentrations in brain. Cancer Chemother Pharmacol.; 25: 320-5. (Pubitemid 20048637)
39. Carman AJ, Mills JH, Krenz A, Kim DG, Bynoe MS (2011) Adenosine receptor signaling modulates permeability of the blood-brain barrier.J Neurosci.; 31: 13272-80.
40. Stopa B, Rybarska J, Drozd A, Konieczny L, Kró l M, et al. (2006) Albumin binds self-assembling dyes as specific polymolecular ligands. Int J Biol Macromol. 40: 1-8. (Pubitemid 44809402)
41. Crowle AJ, Cline LJ (1977) An improved stain for immunodiffusion tests. J Immunol Methods 17: 379-81. (Pubitemid 8189210)
42. Mittal A, Kaur D, Mittal J (2009) Batch and bulk removal of a triarylmethane dye, Fast Green FCF, from wastewater by adsorption over waste materials. J Hazard Mater 163: 568-77.
43. Côté J, Savard M, Bovenzi V, Dubuc C, Tremblay L, et al. (2010) Selective tumor blood-brain barrier opening with the kinin B2 receptor agonist [Phe(8)psi(CH(2)NH)Arg(9)]-BK in a F98 glioma rat model: an MRI study. Neuropeptides.; 177-85.
44. Bartus RT, Elliott PJ, Dean RL, Hayward NJ, Nagle TL, et al. (1996) Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7. Exp Neurol. 142: 14-28. (Pubitemid 26381377)
45. Lagas JS, van Waterschoot RA, Sparidans RW, Wagenaar E, Beijnen JH, et al. (2010) Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther. 9: 319-26.
46. Agarwal S, Sane R, Gallardo JL, Ohlfest JR, Elmquist WF (2010) Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther. 334: 147-55.
47. Siegal T (2013) Which drug or drug delivery system can change clinical practice for brain tumor therapy? Neuro Oncol. 6: 656-69. Epub 2013 Mar 15.
48. Meng Y, Sohar I, Sleat DE, Richardson JR, Reuhl KR, et al.(2014) Effective intravenous therapy for neurodegenerative disease with a therapeutic enzyme and a Peptide that mediates delivery to the brain. Mol Ther. 22: 547-53. doi: 10.1038/mt.2013.267. Epub 2013 Dec 26.
49. Sands MS (2014) A hitchhiker's guide to the blood-brain barrier: In Trans delivery of a therapeutic enzyme. Mol Ther. 22: 483-484.